Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-08-26 4:12 pm Sale |
2022-08-24 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 2,828,356 4.700% |
-318,368 (-10.12%) |
Filing History |
| 2022-08-19 4:17 pm Unchanged |
2022-08-18 | 13D | TELA Bio, Inc. TELA |
ORBIMED ADVISORS LLC | 3,058,267 16.500% |
0 (Unchanged) |
Filing History |
| 2022-08-18 4:39 pm Purchase |
2022-08-16 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,481,204 19.900% |
3,690,000 (+97.33%) |
Filing History |
| 2022-08-12 2:29 pm Purchase |
2022-08-10 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 5,028,174 6.900% |
5,028,174 (New Position) |
Filing History |
| 2022-08-08 4:26 pm Sale |
2022-08-04 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 3,146,724 5.400% |
-387,813 (-10.97%) |
Filing History |
| 2022-07-05 4:30 pm Sale |
2022-07-05 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 1,829,436 4.700% |
-35,285 (-1.89%) |
Filing History |
| 2022-06-28 4:22 pm Sale |
2022-06-24 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 3,534,537 6.900% |
-306,027 (-7.97%) |
Filing History |
| 2022-05-05 4:56 pm Purchase |
2022-05-03 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 6,841,423 12.600% |
894,100 (+15.03%) |
Filing History |
| 2022-04-08 5:20 pm Sale |
2022-04-06 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 3,840,564 7.600% |
-427,000 (-10.01%) |
Filing History |
| 2022-04-01 5:06 pm Unchanged |
2022-03-29 | 13D | PMV Pharmaceuticals, Inc. PMVP |
ORBIMED ADVISORS LLC | 6,589,330 14.500% |
0 (Unchanged) |
Filing History |
| 2022-03-15 4:30 pm Unchanged |
2022-03-10 | 13D | Sierra Oncology, Inc. SRRA |
ORBIMED ADVISORS LLC | 3,044,753 12.200% |
0 (Unchanged) |
Filing History |
| 2022-02-11 5:09 pm Sale |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ORBIMED ADVISORS LLC | 631,000 1.220% |
-1,080,305 (-63.13%) |
Filing History |
| 2022-02-11 5:08 pm Purchase |
2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 61,212 6.400% |
12 (+0.02%) |
Filing History |
| 2022-02-11 4:58 pm Purchase |
2021-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
ORBIMED ADVISORS LLC | 350,641 5.300% |
24,681 (+7.57%) |
Filing History |
| 2022-02-11 4:57 pm Unchanged |
2021-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA |
ORBIMED ADVISORS LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-11 4:51 pm Purchase |
2021-12-31 | 13G | VectivBio Holding AG VECT |
ORBIMED ADVISORS LLC | 4,903,504 14.000% |
73,500 (+1.52%) |
Filing History |
| 2022-02-11 4:49 pm Sale |
2021-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
ORBIMED ADVISORS LLC | 5,456,780 7.400% |
-87,432 (-1.58%) |
Filing History |
| 2022-02-11 4:48 pm Sale |
2021-12-31 | 13G | Strongbridge Biopharma plc SBBP |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,986,869 (Position Closed) |
Filing History |
| 2022-02-11 4:46 pm Purchase |
2021-12-31 | 13G | Sonendo, Inc. SONX |
ORBIMED ADVISORS LLC | 49 7.500% |
49 (New Position) |
Filing History |
| 2022-02-11 4:42 pm Purchase |
2021-12-31 | 13G | RxSight, Inc. RXST |
ORBIMED ADVISORS LLC | 1,062,500 3.900% |
1,062,500 (New Position) |
Filing History |